Objective: To determine the association of conventional cardiovascular risk factors, markers of platelet activation, and thrombogenic blood-borne microvesicles with white matter hyperintensity (WMH) load and progression in recently menopausal women.
The objective of this study was to investigate the relationship between conventional cardiovascular risk factors and numbers of platelet-derived, thrombogenic microvesicles with WMH. Because most studies of WMH were conducted in elderly and predominantly male cohorts, in this longitudinal study, we evaluated WMH load expressed as WMH volume referenced to total white matter (WM) volume in healthy, recently menopausal women without a history of cardiovascular or cerebrovascular disease. METHODS Subjects. KEEPS (NCT000154180) was a multicenter, randomized, double-blinded, placebo-controlled clinical trial in healthy, recently menopausal women (n 5 728) without a history of cardiovascular disease. The study was designed to test the "critical period hypothesis" that hormone therapy started early in menopause (ages 42-59 years, within 6 months to 3 years past last menses) would reduce the progression of subclinical atherosclerosis. 20 Progression of atherosclerosis was measured by CIMT and coronary arterial calcification (CAC). All women meeting inclusion and exclusion criteria for KEEPS 20 at Mayo Clinic in Rochester, MN, were invited to participate in the current ancillary MRI study. KEEPS exclusion criteria briefly were CAC score of .50 Agatston units, smoking .10 cigarettes per day, body mass index (BMI) .35 kg/m 2 , history of cardiovascular disease, low-density lipoprotein (LDL) cholesterol .190 mg/dL, triglycerides .400 mg/dL, diagnosis of diabetes, uncontrolled hypertension (systolic blood pressure .150 mm Hg and/or diastolic blood pressure .95 mm Hg), and current or recent (6 months) use of cholesterol-lowering medications (statins, fibrate, or .500 mg/d niacin). It should be noted that women included in the study refrained from aspirin 2 weeks before blood collection. Additional exclusion criteria for enrollment in the KEEPS-MRI study were as follows: 1) contraindications for MRI for safety such as an MRI-incompatible implant or claustrophobia; 2) neurologic diseases that would have an impact on the magnetic resonance measurements such as multiple sclerosis, brain tumors, or epilepsy.
After meeting eligibility for enrollment into the KEEPS-MRI study at Mayo Clinic (n 5 118), 104 women consented to participate in the study. Of these, 3 women were excluded because of neurologic disorders; thus, of the 101 women included in the KEEPS-MRI study, 95 had repeat MRI examinations at 18 months (n 5 92), 36 months (n 5 85), and 48 months (n 5 79) after randomization to 1 of the following: 1) oral conjugated equine estrogen (Premarin, 0.45 mg/d); 2) transdermal 17b-estradiol (skin patch, Climera, 50 mg/d); or 3) placebo pill and patch. To protect the lining of the uterus, progesterone was given orally (Prometrium; micronized progesterone, 200 mg/d) for 12 days each month to both active treatment groups. The KEEPS treatment assignments were blinded at the writing of this manuscript. Each KEEPS participant underwent a medical examination, including body morphometrics (BMI, waist/hip ratio measurements), an MRI scan, standard blood chemistries, highresolution B-mode ultrasound for the assessment of CIMT and CT for the assessment of CAC. 21, 22 All CAC and CIMT results were read centrally by individuals blinded to participant demographics. 22 None of the women in the Mayo Clinic KEEPS-MRI study developed a neurologic or psychiatric disorder such as stroke or depression throughout the duration of the study.
Standard protocol approvals, registrations, and patient consents. This study was approved by the Mayo Clinic Institutional Review Board (IRB protocol #2241). All participants gave written informed consent.
Magnetic resonance imaging. MRI studies were performed on a single 1.5-tesla system, with an 8-channel phased-array head coil (GE Healthcare, Milwaukee, WI) at baseline and at 18, 36, and 48 months. Fluid-attenuated inversion recovery (FLAIR) MRI with repetition time 5 11,000 milliseconds, echo time 5 147 milliseconds, inversion time 5 2,250 milliseconds, 256 3 192 matrix, 1 repetition, bandwidth 16 kHz, 24-cm field of view, and 3-mm interleaved images of the whole head was performed to quantify WMH volume. A 3-dimensional magnetization-prepared rapid acquisition gradient echo (MPRAGE) sequence with repetition time/echo time/inversion time of 7/3/900 milliseconds; flip angle 8°; in-plane resolution of 1.0 mm, and a slice thickness of 1.2 mm was used for the segmentation of WM. All MRIs underwent preprocessing corrections for gradient nonlinearity and intensity nonuniformity.
WMH volumes were derived from a semiautomated segmentation of FLAIR images. All MPRAGE and FLAIR images obtained during the same examination period were coregistered and segmented using Statistical Parametric Mapping. 23 The MPRAGE image was resampled in the FLAIR space and MPRAGE segmentation was used to generate a WM mask to reduce the number of false positives in the WMH segmentation from FLAIR. WMH on FLAIR images were segmented using an automated slice-based seed initialization and region-growing method. The seeds were determined through empirically derived 1.45 times the mode in 1.5-tesla images. The region-growing step consisted of morphologic dilation of the seeds in 3 dimensions followed by k-means clustering of voxels into 5 classes: CSF, gray matter, WM, WMH, and partialvolume averaged WMH. The WMH and partial-volume averaged WMH was added to the seed-initiated regions as WMH. This step of image dilation using k-means clustering to include new WMH voxels was repeated until no more new WMH voxels were added at dilation or until the maximum number of 50, empirically determined, iterations was reached. Finally, the segmented WMH voxels were multiplied with the WM mask.
A trained image analyst (S.W.), blinded to the timeline of the follow-up scans, inspected the segmented WMH mask overlaid on the FLAIR image. Every segmented slice was visually compared with the unprocessed FLAIR images and all false-positive WMH labels that resulted from artifacts were edited to be excluded from the WMH mask. The inspection of WMH masks at 18, 36, and 48 months was performed by visually comparing each new time point with the baseline WMH mask for consistent editing of the artifacts. The volume of the baseline WMH was referenced to the WM volume and expressed as percentage WMH to account for the variations in WM volume at risk of WMH across participants. Longitudinal change in WMH was calculated by subtracting the WMH volume at 18, 36, or 48 months from the baseline WMH volume and was expressed in cubic millimeters of volume change for each follow-up time point.
Blood chemistries. Blood samples were collected from the participants at baseline before randomization to study treatments as previously described. 17 Total cholesterol, LDL cholesterol, and high-density lipoprotein cholesterol, triglycerides, blood glucose, and 17b-estradiol were measured by Kronos Science Laboratories (Phoenix, AZ) and the Mayo Clinic Department of Laboratory Medicine and Pathology (Rochester, MN).
Platelet count and activation assays. Platelet count was determined using a Coulter counter, as previously described. 24 Expression of activated platelet membrane glycoprotein IIb/IIIa complex binding to PAC-1 antibody (an indirect measure of the fibrinogen receptor complex) was measured by flow cytometry. 17, 21, 24 Blood-borne microvesicles. Numbers of activated plateletderived microvesicles and total numbers of thrombogenic (phosphatidylserine-positive defined by annexin V binding) microvesicles were obtained at baseline using binding of fluorophoreconjugated, platelet-specific CD42a antibody and recombinant annexin V, respectively, by flow cytometry. 17, 25 Statistical analysis. Participant characteristics were summarized at the time of the baseline MRI using counts and percentages for categorical variables, and medians, interquartile ranges, and ranges for continuous variables. Trends in WMH were described over time using means and 95% bootstrap confidence intervals. A series of linear regression models were run to examine and test associations of cardiovascular disease markers with 2 outcomes: baseline WMH to WM volume ratio and change in WMH volume. Log transformations were performed on skewed data, as necessary. Regression coefficients, their associated 95% confidence intervals, and p values were estimated for each model. Given 95 subjects and 4 adjustment variables, there was 80% power in the regression models to detect partial R 2 values as small as 0.06 to 0.12 for individual cardiovascular markers. That is, there should be adequate power to detect cardiovascular markers explaining as little as 6% to 12% of the variability in the WMH outcome variables. Both unadjusted and adjusted models were performed for comparison purposes. The adjustment variables included age, time past menopause (TPM) (in months), and apolipoprotein APOE e4 status. These statistical adjustments were considered important because age has been previously reported as a risk factor for WMH progression 13, 26 and the APOE e4 gene has been most consistently identified as a genetic risk factor for cognitive impairment and Alzheimer disease. 27 Studies have also implicated TPM 28 as an influential factor and potential confounder of cardiovascular risk. Outcome measures of atherosclerosis for the KEEPS were CIMT and CAC. These factors were dichotomized such that the categories were as follows: CAC: 0 for CAC 5 0 (no CAC at baseline, n 5 90), 1 for CAC .0 and ,50 (CAC present, n 5 11); CIMT: 0 for CIMT #0.7 mm, 1 for CIMT .0.7 mm. The CIMT value of 0.7 mm was selected because it represents the median value of the distribution at baseline.
RESULTS Characteristics of participants. The demographics of the KEEPS-MRI group at Mayo Clinic reflected the inclusion criteria with conventional cardiovascular risk factors within normative ranges with 66% being never smokers (table 1) . Seven participants had a history of migraines at the onset of the study, and all 7 had their migraines controlled by medication. Of the measures of atherosclerosis, only 11 of the 101 women (12%) had CAC scores .0 and ,50 at baseline; CIMT ranged from 0.65 to 0.76 mm (median 0.69 mm). At baseline, the median (interquartile range) WMH was 1,909 mm 3 (1,537; 2,655). The WMH to WM volume fraction at baseline was 0.88% (0.69%, 1.16%). Associations between WMH and risk factors for cardiovascular disease. There were no associations of either WMH volume at baseline or change in WMH volume at 36 and 48 months with baseline markers of conventional cardiovascular disease risk (BMI, systolic and The change in WMH volume at 36 and 48 months associated (p 5 0.052 and p 5 0.03, respectively; figure 3A ) with numbers of microvesicles expressing surface phosphatidylserine (as measured by binding to annexin V) at baseline after adjusting for covariates. Similarly, an association was observed between plateletderived microvesicles (those positive for CD42a antibody) and change in WMH at 48 months (p 5 0.03; figure 3B ). The plots demonstrating these associations are included as figure e-1 on the Neurology ® Web site at www.neurology.org.
The change in WMH at 48 months was associated with CIMT in an unadjusted model (p 5 0.04), but this association only showed a trend after adjusting for covariates (p 5 0.06; figure 3C ). DISCUSSION Findings of this study demonstrate that 1) WMH load increases with age in healthy, recently menopausal women in their 40s and 50s, and 2) nonconventional cardiovascular risk factors within the blood, in particular, expression of fibrinogen receptor complex on platelets, platelet-derived microvesicles, and thrombogenic (annexin V-positive) microvesicles, are associated with the progression of WMH. These findings are consistent with previous studies conducted on older males and sex-mixed populations indicating that hemostatic factor VIIc activity and fibrinogen, significantly and independently, associate with the prevalence of WMH. 13 Observations from the present study extend these findings to a younger population of healthy, recently menopausal women using thrombogenic microvesicles as markers of potential hemostatic activity.
Female sex is an independent risk factor for development of WMH. 13, 29 Associations between WMH load and cardiovascular risk factors were reported in participants of the Women's Health Initiative who were older than 65 years and had moderate risk of cardiovascular disease. 30 The current study extends these observations by evaluating the WMH load in a cohort of younger and recently menopausal women whose cardiovascular risk profile was low. In this cohort of healthy women of an age closer to the menopausal transition, no associations were found between WMH and conventional cardiovascular risk factors including systolic and diastolic blood pressure, BMI, waist circumference, cholesterol, smoking, and fasting blood glucose levels at baseline. These findings are consistent with findings in healthy, sex-mixed populations, which also did not detect associations of cholesterol levels with WMH volume 11 but in contrast to studies of older populations, which found associations of WMH with blood pressure, BMI, and fasting blood glucose. 10, 19, 31, 32 These discrepancies may relate to the fact that none of the women of the KEEPS-MRI study had uncontrolled hypertension, their BMI was ,30 kg/mm 2 , and fasting glucose was within the normative range. Platelet activation measured by glycoprotein IIb/ IIIa expression, numbers of platelet-derived microvesicles, and total numbers of thrombogenic microvesicles 18 at baseline associated with WMH load and progression in the recently menopausal women. These findings suggest a subsequent and sustained effect of an activated intravascular compartment on WMH. It is noteworthy that the relationship between WMH and platelet-derived microvesicles in the peripheral circulation was only significant with data adjusted for age, because age is associated with increased WMH load in older women. 2, 32 Moreover, the observed variability in changes of WMH load in the KEEPS-MRI study population may be the result of biological variability and hormonal effects of treatment that could not be analyzed because of blinding to treatment randomization. An activated intravascular compartment may lead to a cascade of events that predicate development of arterial lesions in the periphery with subsequent damage to the heart or kidneys. 33, 34 The findings of the current study provide evidence of a similar role for platelet-derived and thrombogenic microvesicles in the brain.
There was an association between CIMT and the longitudinal change in WMH at 48 months in unadjusted models, where the effects of aging are statistically preserved. Although an association between CIMT and WMH load has been reported in older and sex-mixed populations, 19, 35 age was an important modifier of CIMT progression and stroke risk. 36 Previous evaluation of the KEEPS women found a relationship between CIMT, markers of platelet activation, and blood-borne thrombogenic microvesicles, supporting a link between intravascular platelet activation and carotid intima-medial thickening. 17, 37 Although an activated intravascular compartment might appear to influence both CIMT and WMH, the relationship between CIMT and WMH seems to be weaker and dependent on age.
These results should be interpreted with several limitations in mind. First, there may be several mechanisms underlying the pathophysiology of WMH, which were not addressed in this study, such as Table 2 Adjusted regression coefficients of associations of white matter hyperintensity load and progression of white matter hyperintensity with baseline platelet characteristics, numbers of microvesicles, genetic modifiers of WMH load and progression. 11, 38 Second, the Mayo Clinic KEEPS consisted of healthy, well-educated women, most of whom were nonsmokers, and may not reflect the general population of recently menopausal women. However, an advantage of a homogeneous population is that findings may reflect physiologic processes without the confounding effect of manageable cardiovascular risk factors. Finally, the observed associations of WMH with platelet activation factors must be confirmed in future studies of longer duration with a larger sample size.
The findings of the present study indicate that activated platelets are associated with WMH load and progression in recently menopausal women, and thus, modifying activation state of platelets may serve as a therapeutic target to prevent progression of WMH in the brain. The associations between platelet-derived and thrombogenic microvesicles at baseline and WMH progression after 3 to 4 years might suggest that prothrombotic characteristics of the blood contribute to structural changes in the WM of healthy postmenopausal women. As the clinical significance of WMH in younger populations remains controversial, additional research is needed to determine the underlying mechanisms of WMH development and progression in recently menopausal women.
AUTHOR CONTRIBUTIONS
Dr. Raz: design or conceptualization of the study, analysis and interpretation of the data, drafting the manuscript. Dr. Jayachandran, Ms. Tosakulwong, Mr. Lesnick, Ms. Wille, Dr. Murphy, Mr. Senjem, Dr. Gunter, Dr. Vemuri, Dr. Jack: analysis or interpretation of the data, revising the manuscript. Dr. Miller: design or conceptualization of the study, revising the manuscript. Dr. Kantarci: design or conceptualization of the study, analysis or interpretation of the data, revising the manuscript.
ACKNOWLEDGMENT
The authors gratefully acknowledge the KEEPS participants; study coordinator Teresa G. Zais; and Robert D. Litwiller for his technical assistance collecting the blood and performing the platelet functional assays.
STUDY FUNDING
This study was funded by grants from the NIH R21 NS66147 and AG040042 to Kejal Kantarci, HL90639 and AG044170 to Virginia M. Miller, the Aurora Foundation to the Kronos Longevity Research Institute, HD065987, UL1 TR000135, and UL1 RR024150, and the Mayo Foundation. Grant UL1 RR024150 was sponsored by the National Center for Research Resources (NCRR), and grant UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS), both components of the NIH, and the NIH Roadmap for Medical Research. This publication was made possible by CTSA grant UL1 TR000135 from NCATS, a component of the NIH. Contents of this paper are solely the responsibility of the authors and do not necessarily represent the official view of NIH. 
